Page last updated: 2024-09-05

erlotinib hydrochloride and xl147

erlotinib hydrochloride has been researched along with xl147 in 1 studies

Compound Research Comparison

Studies (erlotinib hydrochloride)	Trials (erlotinib hydrochloride)	Recent Studies (post-2010) (erlotinib hydrochloride)	Studies (xl147)	Trials (xl147)	Recent Studies (post-2010) (xl147)
4,353	786	3,033	26	8	25

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bahleda, R; Burris, H; Jiang, J; Lager, J; Liu, L; LoRusso, P; Macé, S; Martini, JF; Soria, JC	1

Trials

1 trial(s) available for erlotinib hydrochloride and xl147

Article	Year
Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors. The oncologist, 2015, Volume: 20, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Quinoxalines; Sulfonamides; Treatment Outcome	2015

Article

Year

Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors.

The oncologist, 2015, Volume: 20, Issue:3

Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Quinoxalines; Sulfonamides; Treatment Outcome

2015